首付款12.5亿美元!三生制药与辉瑞达成PD-1抗体药物合作开发协议,创新药沪深港ETF大涨3%

每日经济新闻
20 May

5月20日,三生制药公告称,其与辉瑞公司就前者自主研发的PD-1/VEGF双特异性抗体SSGJ-707签订了独家许可协议 。(相关个股仅供分析参考,不构成投资建议,下同)首次消息提振,创新药大举上攻,创新药沪深港ETF(517110)大涨3%。根据协议,三生制药将获得12.5亿美元的首付款,以及最高可达48亿美元的开发、注册及销售里程碑付款,外加基于产品在许可地区净销售额的梯度双位数百分比提成 。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10